After the recent approval and launch of twice-yearly HIV prophylactic Yeztugo, Gilead is cleaning up its R&D pipeline. | After the recent approval and launch of twice-yearly HIV prophylactic Yeztugo, ...

Lilly's second-quarter results reported Thursday were still more than fine: $15.5 billion in revenue beat Wall Street ...

Before you buy stock in Novo Nordisk, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Novo Nordisk wasn ...

SERB Pharmaceuticals plans to buy Y-mAbs Pharmaceuticals in a $412 million all-cash deal. CorMedix bought Melinta ...

Weight-loss drugs significantly improve health, though they’re also tied to increased spending on other medical care that’s ...

Shares rose for a second day, in a rally sparked by rival Eli Lilly (LLY) reporting less-than-stellar trial results for an ...

In the wake of this sell-off, a critical question arises about whether LLY stock represents a buying opportunity.

Eli Lilly’s orforglipron cut body weight to a lesser extent than rival Novo Nordisk’s semaglutide, falling into analysts’ ...

The investment conglomerate reported a higher-than-expected profit, aided by a recovery in its te ...

Shares of Novo Nordisk climbed 4.29% during Friday’s pre-market trading session, after rival Eli Lilly’s Phase 3 ATTAIN-1 ...

Novo Nordisk shares jumped more than 5% on Friday, extending Thursday’s rally, after Eli Lilly’s obesity pill data fell short of market expectations.

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...